



SDI Review Form 1.6

Journal Name:	Journal of Advances in Medicine and Medical Research
Manuscript Number:	Ms_JAMMR_49377
Title of the Manuscript:	The effect of phosphodiesterase type5 inhibitors on the development of retinopathy of prematurity: A Randomized Clinical Trial
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Compulsory REVISION comments</p>	<p>The active ingredient in Sildenafil must be clearly stated</p> <p>In any study involving a control group, the size of the experimental group(case group) should be equal to that of the control group.</p> <p>Provide a heading for your conclusion</p> <p>Provide a heading for and make recommendation from this study</p>	<p>Response: We thank you for taking the time to review our manuscript, and we also Thank you very much for this valuable comment. Please find our response to this comment in the introduction of the revised manuscript. We added the following to the revised manuscript. VIAGRA (sildenafil citrate), an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3d] pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate.</p> <p>Response: Thank you very much for this comment, actually the size of the experimental case group is equal to that of the control group. In this study 52 patients in sildenafil and 50 patients in placebo group were studied, there was a typing error in abstract, but in figure 1 we explained study design and subject selection. Also you can find it in tables and all of text.</p> <p>Response: Thanks for this valuable comment, we added a heading for conclusion to the revised manuscript.</p> <p>In conclusion, this study shows that sildenafil administration did not significantly affect the incidence of ROP in premature infants treated with oxygen. Our study has some limitations like as the sample size was small, Perhaps, if the population size was bigger a better result could be observed. We matched the control group as close as possible to the index cases by matching for gestation, birth weight, gender and place of birth. Further work on the retinal effects of sildenafil may be useful in determining whether it truly is a good therapy for preventing of pathogenesis of ROP and Prospective trials may be useful to establish a definite safety profile.</p>
<p>Minor REVISION comments</p>	<p>Emphasise how this study can reduce the population of the visually impaired in your locality and world at large.</p>	<p>Response: Thank you very much for this comment, actually in last paragraph in discussion section we mention it: For the reviewer consideration: Through the past 4 year's relative improvement of neonatal intensive care and monitoring of oxygen therapy result in decreasing incidence of ROP in our center</p>



SDI Review Form 1.6

<p>Optional/General comments</p>	<p>The title should reflect the location of the study group. This would help in future comparative studies and review of literature</p>	<p>Response: Thank you very much for this valuable comment, we added the following to the revised manuscript title:</p> <p>The effect of phosphodiesterase type5 inhibitors on the development of retinopathy of prematurity in Ahvaz preterm infants: A Randomized Clinical Trial</p>
---	---	---

PART 2:

	<p>Reviewer's comment</p>	<p>Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i></p>
<p>Are there ethical issues in this manuscript?</p>	<p><i>(If yes, Kindly please write down the ethical issues here in details)</i></p>	